期刊文献+

HBV-SAg特异性靶细胞系的构建 被引量:6

Production of HBV surface antigen specific target cell
原文传递
导出
摘要 目的 研究特异性细胞免疫反应在病毒性肝炎发生发展中的作用及观察药物等对细胞免疫反应的影响。方法 用DNA 重组技术构建逆转录病毒重组质粒PLXSNS,以电穿孔方法转入PA317 细胞,筛选高表达克隆,收集其假病毒颗粒感染EL4 细胞,经有限稀释选择高表达克隆。结果 重组质粒转染PA317 细胞后,53 个克隆形成(1∶10 传代),在24 孔板中扩增后有7 个克隆细胞上清HBsAg 阳性。用HBsAg A值(曾称OD值) 最高克隆的假病毒感染EL4 细胞,再经有限稀释得到稳定、高效表达HBsAg 的靶细胞系(EL4S),在体外传100 代以上,HBsAg 仍能高效表达(48 小时上清中HBsAg 的A值达0-85)。经检测PLXSNS及重组腺病毒rAdB72S免疫后小鼠对HBsAg 特异的细胞免疫反应,得到较为满意的结果。结论 我们成功构建了稳定表达HBsAg 的靶细胞,对研究HBsAg Objective To analyze the hepatitis B virus surface antigen (HBsAg) specific cytotoxic T cell(CTL) response during hepatitis development and investigate the effect of some factors on CTL response. Methods The recombinant retrovirus plasmid PLXSN S was tranferred into PA317 by electroporation and the pseudoviruses produced from PA317 were used to infect EL 4. Clones which highly expressed HBsAg were selected with limited dilution.Results A clone expressing HBsAg the highest ( A =0.85 in supernatant at 48th hour) was obtained which steadly expressed HBsAg in vitro after at least 100 passages. It worked very well when used as target cells in CTL response after C 57 mice immunized with PLXSN S and recombinant adenovirus vector (rAdv B 7 2 S).Conclusion We constructed HBsAg specific target cell line which steadly expressed HBsAg. It may play an important role in HBsAg CTL reponse and immunopathogenetic mechanisms of hepatitis B.
出处 《中华实验和临床病毒学杂志》 CAS CSCD 1999年第3期231-234,共4页 Chinese Journal of Experimental and Clinical Virology
基金 国家自然科学基金
关键词 乙型肝炎 靶细胞 细胞免疫 Hepatitis B Target cell Cell mediated immunization
  • 相关文献

参考文献3

  • 1Oscar B R,Hepatology,1997年,25卷,470页
  • 2Chen Leiping,J Experiment Med,1994年,179卷,523页
  • 3Shu Peiyuan,J Infect Dis,1994年,169卷,633页

同被引文献33

  • 1任鹏康,黄倩.靶向重组腺病毒载体研究进展及其在肿瘤基因治疗中的应用[J].国际病毒学杂志,2006,13(2):54-58. 被引量:2
  • 2罗红兵,郑群.慢性乙型肝炎基因治疗研究进展[J].国际病毒学杂志,2006,13(2):62-64. 被引量:1
  • 3Guidotti LG, Ishikawa T, Hobbs MV. Intracellular inactivation of the hepatitis B virus by cytotoxie T lymphocytes. Immunity, 1996, 4 (1) : 25-36.
  • 4Chisaii FV, Ferrari C. Hepatitis B virus immunopathology. springer semin immunopathol, 1995, 17 (2-3) : 261-281.
  • 5Nguyen MH, Keeffe EB. Chronic hepatitis B : early viral suppression and long-term outcomes of therapy with oral nucleos(t) ides. J viral Hepat, 2009, 16(3) : 149-155.
  • 6Thimme R, Wieland S, Steiger C, et al. CD8 ( + ) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Viral, 2003, 77 ( 1 ) : 68-76.
  • 7Chisari FV. Hepatitis B virus transgenic mice : insights into the virus and the disease. Hepatology, 1995, 22(4) : 1316-1325.
  • 8Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mecha- nism in transgenic mice. Proc Natl Acad Sci USA, 1994, 91 (9) : 3764-3768.
  • 9Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol, 2002, 76(21): 10702-10707.
  • 10Huang LR, Wu HL, Chen PJ, et al. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA, 2006, 103(47) : 17862-17867.

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部